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SUMMARY 
The establishment of hybridomas after fusion of X63-Ag8.653 mouse myeloma 
cells and splenocytes from BALB/c mice hyperimmunized against human astrocytomas 
is presented. The animals were primed with 5 x 106 chemically modified uncultured or 
cultured glioma cells. Six weeks after the last immunization step an intrasplenal booster 
injection was administrated and 3 days later the spleen cells were prepared for fusion 
experiments. According to the specificity analysis of the generated antibodies 7 
hybridoma products (MUC 7-22, MUC 8-22, MUC 10-22, MUC 11-22, MUC 14-22, 
MUC 15-22 and MUC 2-63) react with gliomas, neuroblastomas nd melanomas as 
well as with embryonic and fetal cells but do not recognize non-neurogenic tumors. The 
selected monoclonal ntibodies (McAbs) of IgG~ and IgG2a isotypes are not extensively 
characterized but these antibodies have been demonstrated to be reactive with a panel 
of glioma cell lines with varying patterns of antigen distribution. Using the McAbs 
described above and a series of cryosections of glioma biopsies and paraff'm sections 
of the same material as well as glioma cultures established from these, variable antigenic 
profiles among lioma cell populations could be demonstrated. From these results it is 
evident hat there is not only a distinct degree of antigenic heterogeneity among and 
within brain tumors, but also that the pattern of antigenic expression can change 
continuously. Some of the glioma associated antigens recognized by the selected 
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antibodies persist af er fixation with methanol/acetone and Karnovsky's fixative and 
probably are oncoembryonic/oncofetal antigen(s). The data suggest that the use of 
McAbs recognizing tumor associated oncofetal antigens in immunohistochemistry 
facilitates objective typing of intracranial malignancies and precise analysis of fine 
needle brain/tumor biopsies in a sensitive and reproducible manner. 
Key words: Human gliomas; Monoclonal antibodies; Immunohistochemistry; Onco- 
fetal antigens 
INTRODUCTION 
The development of adequate immunologic methods is a fundamental condition 
for the investigation of membrane alterations and the resulting antigenicity of tumor 
cells. By the establishment of the hybridoma technique (KOhler and Milstein 1975) and 
the use of monoclonal ntibodies (McAbs) in the analysis of the antigenic determinants 
of the tumor cell membrane, not only the existence of tumor associated antigens in 
spontaneous and experimental brain tumors has been demonstrated (Schnegg et al. 
1981; Sikora and Phillips 1981; Coakham et al. 1982; Wikstrand and Bigner 1982; 
Stavrou et al. 1983; de Muralt et al. 1985), but also efforts in developing valuable 
diagnostic methods received considerable stimulation (review by Bullard and Bigner 
1985). Numerous attempts have been made to produce McAbs which recognize glioma 
cells exclusively. So far, there is a number of monoclonal reagents binding antigens 
expressed on tumor cells but also on normal glia cells (Krajewski et al. 1986). 
In order to generate molecules useful to assist in the more accurate and objective 
typing of intracranial malignancies we established immunoglobulin secreting 
hybridomas using cultured and uncultured human astrocytoma cells as antigen. In the 
following we describe the recognition pattern of selected McAbs with their high degree 
of specificity utilizing cell u tures of different origin as well as tissue samples obtained 
from neurogenic and non-neurogenic tumors and normal organs. 
MATERIALS AND METHODS 
Human lumors 
Fresh tumor samples from biopsy material were immediately frozen and pre- 
served in liquid nitrogen containers or bio-freezers until use for histochemistry or 
immunization. Additional tumor specimens were fixed in Bouin's solution, Karnovsky's 
fixative and methanol/acetone mixture and embedded in paraffin (45 °C). Sections of 
frozen and paraffin material were used for conventional histology as well as for 
immunohistochemistry. For control experiments tissue fragments of different regions of 
normal brain and other organs were obtained 90 min post-mortem and processed 
analogous. 
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Human tumor cell cultures 
For establishment of primary cultures, fragments of biopsy material obtained 
under sterile conditions were placed in Falcon flasks and covered with medium M 199 
(with Hank's salts, Seromed ®, Berlin, F.R.G. or RPMI 1640), supplemented with 20~'o 
inactivated FBS (fetal bovine serum, Flow laboratories, Meckenheim, F.R.G.), 10 ml 
8.8 ~ NaHCO3, 100 000 IU penicillin G, 0.1 g streptomycin, 0.1 g neomycin, and 3.4 ml 
20 mM glutamin per litre medium. Cultures were incubated at 37 °C in air with 6~/o CO 2 
and high humidity. For in vitro passaging of the cells, primary cultures were splitted 1 : 2 
using saline trypsin-versene (STV) solution. Long term cultures were fed with M 199 
or RPMI 1640 (Seromed ®, Berlin, F.R.G.), supplemented with 10~ inactivated FBS, 
10 ml 8.8~o NaHCO3, 100000 IU penicillin G, 0.1 g streptomycin, and 3.4 ml (M 199) 
or 10 ml (RPMI 1640) 20 mM glutamin per litre medium and karyotyped from time to 
time. 
Human embryonic cell cultures 
Fragments from brain anlage as well as from thoracic and abdominal segments 
of two embryos (9th and 1 lth weeks of development) were layered in plastic flasks. In
addition, the rest of the embryonic material was prepared asa fine cell suspension and 
placed in tissue culture flasks. All primary cultures were fed with HC medium (450 ml 
DMEM, 75 ml FBS, 50 ml NCTC-135 medium, Flow Lab., Meckenheim, F.R.G., 5 ml 
sodium pyruvate, 0.1 g neomycin) initially supplemented with 20 ~ inactivated FB S and 
the subcultures were maintained in the same medium containing 10~ FBS. Sub- 
sequently, the cultures were serially transferred using STV solution twice a week. All 
cultures were incubated at 37 °C humidified atmosphere of 6~ CO 2 in air. 
Animals 
BALB/c and BALB/c-nu/nu mice used for immunization and production of 
ascitic fluid were taken from our barrier maintained colony. 
Mouse myeloma line 
The myeloma cell line X63-Ag8.653 (Kearney et al. 1979) was used for fusion 
experiments. The myeloma cells were grown in HC medium supplemented with 10% 
FBS. Two days before fusion, the ceils were fed with HC medium containing 20% FBS. 
Establishment ofmurine hybridoma clones (MUC) 
BALB/c mice were immunized i.p. 3 times (lst, 8th, 15th day) with 5 x 10 6 TNBS 
(2,4,6-trinitrobenzenesulfonic ac d) modified whole human tumor cells cultivated in 
vitro (85HG-3 and 85HG-63 astrocytoma cells) and with cells prepared from biopsy 
material of a malignant glioma (N 22/85: astrocytoma grade III). TNBS modification 
was carried out as described by Stavrou et al. (1980, 1981). Briefly, mechanically 
harvested cells (5 x 10 6) in 0.1 ml medium were incubated with 0.1 ml of 0.1 M TNB S 
dissolved in 0.05 M PBS (pH 7.4) for 10 min at 37 °C. Aseptically removed tumor 
fragments were washed with sterile PBS, immediately minced and passed through a 
sterile wire-gauze. The cell suspension was frozen and stored at - 80 °C. Six weeks 
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after the last immunization an intrasplenal booster injection of 5 x 105 native tumor 
cells, harvested from culture vessels u ing STV solution or thawed from frozen tumor 
samples, was performed. Three days later spleen ceils were fused with X63-Ag8.653 
myeloma cells. Hybrids were selected as described previously (Stavrou et al. 1983, 
1985). Supernatants from hybridoma cultures were tested for antibody reactivity with 
glioma tissue and glioma cell cultures. 
Antibody binding assays 
Screening for immunoglobulin secretion by hybridomas and for identifying 
hybridoma clones of interest was performed using the following techniques: (a) micro- 
ELISA (Posner et al. 1982); (b) indirect immunoperoxidase stain, carried out on cells 
grown in Terasaki plates and on tissue sections prepared from frozen as well as from 
fixed (methanol/acetone, Bouin, Karnovsky) and paraffin-embedded (45°C) material; 
(c) indirect immunofluorescence test as reported by Stavrou et al. (1978); and (d) 125I 
radioimmunoassay (125I-RIA) using 10 x 105 target cells incubated on U-bottomed 
microtest plates with culture fluid. Details of the performance protocols have been 
published (Stavrou et al. 1983; de Muralt et al. 1985). 
Flow cytometry analysis 
Fluorescent activated cell sorter procedures were performed in buffer consisting 
of phosphate-buffered saline, 2.5~o fetal bovine serum, and 0.02~o NaN 3. Stained cells 
were analysed after fixation with 1 ~o paraformaldehyde (Lanier and Warner 1981) by 
flow cytometry using an EPICS 752 (Coulter Electronics). The EPICS was operated 
at 488nm excitation wavelength with the photomultipler tube at 650-800V. 
Fluorescence intensity was expressed on a log scale of 256 channels. Living cells were 
gated on forward angel lightscatter and 90 degree log integrated lightscatter. Indirect 
immunofluorescence was used for the hybridoma superuatants directed against glioma 
cell surface determinants. The supematants were incubated for 60 min with 106 cells 
on ice, followed by 2 washes with PBS, and incubated on ice with rabbit anti-mouse 
FITC (Dakopatts F 261). 
As control, the isotype-matched irrelevant mouse myeloma protein UPC 10 
(Sigma No. M-9144) diluted 1 : 100 was used. 
Concentration and partial characterization f McAbs 
The enrichment of McAbs from hybridoma supernatants was performed by using 
saturated ammonium sulfate solution (Jonak 1980). The identification of hybridoma 
products was carried out by using the two-dimensional double-immunodiffusion, 
immunoelectrophoresis andSDS-PAGE tests. The isotype of monoclonal immuno- 
globulin was determined by using micro-Ouchterlony immunodiffusion and micro- 
titration ELISA subtyping system (Mouse-typer TM sub-isotyping kit, Bio-Rad Labo- 
ratories, Richmond, LA, U.S.A.) and appropriate polyclonal antisera (Miles Labo- 
ratories, Naperville, IL, U.S.A.). 
In order to estimate he binding specificity of selected hybridoma products a series 
of absorption experiments were performed. Hybridoma supernatants were absorbed 
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with cultured human cells and human brain powder and the remaining activity was then 
tested by antibody-binding tests u ing cultured glioma cells as targets. For quantitative 
absorptions increasing numbers ofglioma cells were suspended in aliquots of a constant 
dilution of hybridoma supernatants and after incubation the remaining activity was 
measured by micro-ELISA. The absorption procedures have been described in detail 
elsewhere (Stavrou et al. 1983). 
RESULTS 
Establishment and selection of antibody secreting hybridomas 
From 2 fusion experiments between X63-Ag8.653 myeloma cells and immune 
spleen cells against glioma cells, hybrids appeared between 6 and 10 days following 
fusion and were seen i  151 wells of Linbro plates. Screening of the supernatants of 
these hybridoma cultures, composed of numerous single colonies, howed that in 24 
wells hybrids were secreting antibodies reacting to giioma cells used for immunization 
as well as to different human target cells including embryonic ells. 
Specificity analysis and isotyping of interesting monoclonal immunoglobulins 
Selected hybridomas that secreted monoclonal antibodies binding to various 
target tumor cells were sequentially cloned 3 times by limiting dilution method. In each 
cloning step they were examined for specificity or cross-reactivity b testing culture 
supernatants for antibody binding to human tumor cells of different origin and human 
peripheral blood monocytes. The eleven murine clones (MUC) secreting antibodies 
which did not react with control cells were chosen for further specificity analysis. The 
selected clonal products described here were designated as MUC 1-3, MUC 2-3, 
MUC 3-3, MUC 4-3, MUC 5-3 and MUC 7-22, MUC 8-22, MUC 10-22, MUC 11-22, 
MUC 14-22, MUC 15-22 and MUC 2-63. During the specificity analysis of these 11 
monoclonal anti-glioma ntibodies it was observed that the hybridoma products 
MUC 1-3 to MUC 5-3 reacted not only with neuroectodermal tumors but also with 
normal brain tissue. Whereas the r st of the McAbs (MUC 7-22 to MUC 15-22 and 
MUC 2-63) reacted with neuroectodermal tumors but did not recognize normal brain 
except for a few cells in brain cortex particularly bordering o  tumor tissue. In this 
regard it should be stressed that the antibodies MUC 7-22 to MUC 15-22 and 
MUC 2-63 also recognized human embryonic brain cells (Table 1). 
In order to ensure the specificity of the selected hybridoma products, a series of 
quantitative absorption experiments u ing glioma cells as well as normal brain tissue 
were performed. A representative sample of the obtained ata showed that monoclonal 
antibodies secreted by the hybridoma clones MUC 7-22 and MUC 8-22 did not lose 
their binding capability to glioma cells, including the immunizing tumor cells, after 
absorption with normal human brain tissue. On the other hand, the quantitative 
absorption with giioma cells derived from the tumor used for immunization gradually 
reduced the binding activity of MUC 7-22 and MUC 8-22 to glioma cells. 
By means of immunodiffusion and immunoelectrophoresis tests the McAbs 
MUC 7-22, MUC 8-22, MUC 10-22, MUC 11-22, MUC 14-22 and MUC 15-22 were 
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TABLE 1 
REACTIVITY OF MONOCLONAL ANTIBODIES AGAINST HUMAN ASTROCYTOMAS WITH 
HUMAN CELLS AND TISSUES OF DIFFERENT ORIGIN ESTIMATED BY THE INDIRECT 
IMMUNOPEROXIDASE METHOD 
Tissue or 
cell type 
Murine monoclonal antibodies 
MUC 1-3/MUC 5-3 MUC 7-22/MUC 15-22 MUC 2-63 
1. Normal brain + - - 
(1. occip., m., 70 yrs) (1) 
2. Embryonic brain cells + + + 
(brain anlage, 9 wks) (1) 
3. Fetal brain cells + + + 
(22 and 24 wks) (2) 
4. Blood monocytes - - - 
(healthy donors) (5) 
5. Lymphoma (2) - - - 
6. Colon carcinoma (3) + ( + )* - 
7. Breast carcinoma (4) - ( + ) - 
8. Gastric carcinoma (3) n.t. - - 
9. Renal carcinoma cells (2) + - - 
10. Teratocarcinoma (testis) (I) n.t. ( + ) ( + ) 
11. Meningioma (endotheliomatous) (4) - ( + ) - 
12. Meningioma (haemangioblastic) (1) - - - 
13. Melanoma (8) + + + 
14. Neuroblastoma cells (I) + + + 
15. Glioma (42) + + + 
* A few positive cells; n.t., not tested; no. tested in parentheses. 
identif ied to be IgG2a. The isotype of  MUC 2-63 antibodies was IgG 1 according to gel 
diffusion and microt itrat ion EL ISA  subtyping system. 
Binding properties of McAbs to fixed and paraffin embedded tissue sections 
The immunoreact ions  of  the gl iomas tested with the antibodies MUC 7-22 to 
MUC 15-22 are summar ized in Table 2. All g l iomas studied bound McAbs  in different 
patterns. In most  instances tumors conta ined small areas of  posit ive cells or single 
posit ive cells d isseminated in the tumor  tissue. In 2 cases tumors had large regions of  
posit ive cells (more than 50~ of  the neoplast ic cells). Mater ia l  fixed with methanol /  
acetone or Karnovsky 's  solution and embedded in paraffin (45 ° C) conta ined signifi- 
cantly more stained cells as compared  to preparat ions after f ixation with Bouin 's  fixative 
(Table 3). Tumor  cells in areas with characterist ic architectural and cytological features 
of  well differentiated astrocytomas were usually stained and showed different staining 
intensities. In all posit ive cells the react ion product  was local ized in cytoplasm, whereas 
nuclei were ordinari ly negative. No  staining was obtained within the intercellular spaces, 
mononuc lear  infiltrates, necrosis, abnormal  stromal reactions, vascular  prol iferations, 
and normal  brain areas bordering on tumor  tissue. 
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TABLE 3 
REACTIVITY OF THREE MONOCLONAL ANTIGLIOMA IMMUNOGLOBULIN S TO S ELECTED 
GLIOMA TISSUE UNDER VARYING CONDITIONS BY INDIRECT IMMUNOPEROXIDASE 
METHOD* 
Monoclonal Antibody Target Frozen sections 
products isotype tumors 
Stability of glioma antigen(s) in paraffin 
sections after fixation with 
Native Acetone Bouin's Methanol/ Karnovsky's 
fixed fixative acetone fixative 
MUC 8-22 IgG2a 
MUC 10-22 IgG2a 
MUC 14-22 IgG2a 
N23/86 + + + + + + + + 
N24/86 + + + + + + + + + 
N29/86 + + + + + + + + + + + 
N31/86 + + + + + + + + + + + + 
N32/86 + + + + + - + + + - 
N33/86 + + + + + + - + + + + 
N23/86 + + + + + + + + 
N24/86 + + + + + + + 
N29/86 + + + + + + + + + + n.t. 
N31/86 + + + + + + + + + + + 
N32/86 + + + + + + + + + + + 
N33/86 + + + + + + + + + + - 
N23/86 + + + + + + + + + 
N24/86 + + + + + + + 
N29/86 + + + + + + + 
N31/86 + + + + + + + + + + + + 
N32/86 + + + n.t. + + + + + - 
N33/86 + + + + + + + + + + + + 
* Scale: - ,  negative; +,  some positive cells; + +, < 50% positive cells; + + +, > 50% positive cells. 
Binding properties of McAbs to glioma cryosections 
The  character i s t i c  b ind ing  des ign  o f  McAbs  MUC 7-22 to MUC 15-22 invest i -  
gated  on  g l ioma f rozen  sect ions  s shown in Tab le  2. A l l  6 McAbs  bound in tense ly  to  
all tumor  spec imens  tes ted .  Moreover ,  re la t ive  b ind ing  act iv i t ies  o f  the  McAbs  were  not  
comparab le  among c ryosect ions  and  para f f in  p reparat ions .  A l though the  number  o f  
immunosta ined  cel ls  us ing  a pane l  o f  McAbs  d i f fers  f rom tumor  to  tumor ,  it is ev ident  
that  c ryosect ions  conta ined  throughout  essent ia l l y  more  cei ls  w i th  recogn izab le  ant i -  
gen ic  determinants  than  the  para f f 'm embedded mater ia l .  S t rong  c ross - react iv i t ies  were  
found  w i th  all g l iomas ,  par t i cu la r ly  w i th  as t rocytomas  as l i s ted  in Tab le  2. 
Binding properties of McAbs to glioma cells and embryonic brain cells cultured in vitro 
The  ser ies  o f  cei l  cu l tu res  tes ted  inc lude  shor t - te rm cu l tu res  as  w l l as  permanent  
tumor  cell  l ines.  As  shown in Tab le  4, all McAbs  bound w i th  h igh  capac i ty  to  cel ls  
der ived  f rom human g l iomas ,  neurob las tomas ,  me lanomas  and  f rom human embryon ic  
b ra in  an lage .  No  react ion  was  observed  w i th  non-neuroectodermal  cel l  l ines  tes ted  
(Tab le  4)  and  w i th  per iphera l  b lood  mononuc lear  c l ls .  
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Concluding from the extinction data obtained by ELISA the antibodies 
MUC 8-22 and MUC 14-22 react strongly with the 2 glioblastoma cell lines (85HG-64, 
85 HG-65) and in a lesser intensity with t e rest of the tested glioma cultures. Strong 
binding was also observed with embryonic ells of different origin and especially with 
those from brain anlage. 
The cellular distribution of glioma associated antigen(s) reacting with selected 
McAbs was studied by indirect immunofluorescence procedure on frozen sections of 
glioma tissue and also on cell cultures (Fig. 1). In general, the labelling with MUC 2-63 
antibody was very high and the fluorescent structures were localized predominantly on 
the cell surface and occasionally in the cytoplasm of native cells. On the other hand, 
the epitopes reacting with MUC 7-22 to MUC 15-22 were confined mainly to the 
cytoplasm near the cell membrane. Particularly in acetone-fixed cells labelling of 
cytoplasmic organelles with MUC7-22 to MUC 15-22 was remarkably strong, 
although unfixed cells were unlabelled or only marginally labelled. 
Binding properties of McAb to glioma cells in flow cytometry analysis 
Flow cytometry analysis gave an interesting staining pattern showing the hetero- 
geneity of surface expression of the recognized antigen(s). As shown in Table 5 the 
percentage of stained cells differs from 16 to 65~o when our set of McAbs is tested on 
various glioma cell lines. Fig. 2 demonstrates the recognition pattern of MUC 7-22 to 
MUC 15-22 on the cell line 85HG-65. 
DISCUSSION 
The results presented here indicate that a series of hybridomas originated by 
fusing of X63-Ag8.653 murine myeloma cells with mouse splenocytes ofmice sensitized 
against human astrocytomas. A number of the hybridomas obtained produced no 
detectable antibodies or they stopped producing them after a few in vitro passages. The 
majority of the immunoglobulin-producing hybridomas, however, secretes antibodies 
binding a large number of normal and transformed human cells. 
Seven hybridoma clones (MUC 7-22 to MUC 15-22 and MUC 2-63) obtained 
using a novel immunization schedule were selected according to binding properties of 
their products with human neuroectodermal tissue under certain conditions. Namely, 
the binding capability of the McAbs was tested on sections of fresh and paraffin- 
embedded (45 ° C) material as well as on short-time in vitro cultured brain d glioma 
cells. According to the results of different binding tests, the monoclonal products 
MUC 7-22 to MUC 15-22 recognized antigenic determinants which were commonly 
expressed on neoplastically transformed glia cells, normal cells of the embryonic brain 
anlage and a few cells in brain areas next to the tumor tissue. 
Fig. 1. Glioma cell line derived from a human astrocytoma grade III consists entirely of bipolar or stellate 
cells (A, 42nd passage). Binding capacity of MUC 2-63 and MUC 8-22 monoclonal antibodies to glioma 
cells by indirect immunofluorescence staining under different conditions (B-E). The unfixed cells (B: 
monolayer; E: cytospin preparation) show binding for MUC 2-63 on the cell membrane. Acetone-fixed 
glioma cells (C: monolayer; D: cryosection) tested for reactivity with MUC 8-22 antibody demonstrate 
fluorescent structures mainly in the cytoplasm. (A-C: × 200; D,E: x 125). 
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85 HG-65cells 
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Fig. 2. Fluorescent-activated c ll sorting profiles of glioma associated antigens on 85HG-65 human brain 
tumor cells recognized by the W 6-32 (against human class-I antigens) and the MUC antibodies 
(MUC 15-22:49 % ; MUC 8-22:31% ; MUC 11-22:35 %; MUC 7-22: 24% ; MUC 10-22: 34%; MUC 12-22: 
38 %; MUC 14-22:35 % positive cells). Evaluated against the isotype control UPC 10 (dark field). 
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The binding results using paralTm and frozen sections as well as cell cultures 
indicated that an ideal screening method that allows the identification fglioma ntigens 
in native form, does not exist so far (Roholl et al. 1985; Taub et al. 1985). As shown 
in Table 3 tissue sections from material fixed with various chemicals and embedded in
paraffin have their limitations. Fixation with coagulative fixatives (Bouin's) or cross- 
linkers (e.g., formaldehyde) obviously alters tumor-associated membrane antigens so 
that hey mostly cannot be recognized by monoclonal ntibodies. From all fixatives used 
in this study methanol/acetone or the Karnovsky paraformaldehyde/glutaraldehyde 
mixture and paraffin embedding at 45 ° C have been shown to be acceptable procedures. 
It is also apparent that air-dried, frozen sections (Kemshead and Coakham 1983; 
Coakham et al. 1985) or cryosections mounted on slides, using a combination ofdrying 
at room temperature and fixation with cold acetone (5 min, 4 ° C), are to be preferred 
to paraffin sections. However, the cytological evaluation of immunostained frozen 
sections can certainly introduce considerable difficulties in the cell characterization and 
particularly in the distinction between ormal, reactive and neoplastically transformed 
cells. Depending on the binding behaviour with human ormal and malignant tissue of 
different organs, the generated antibodies could be divided into 2 groups; the first group 
comprising of 5 antibodies (MUC 1-3 to MUC 5-3) shows reactivity against a large 
series of normal and tumor tissues. The second group of antibodies (MUC 7-22 to 
MUC 15-22 and MUC 2-63) differed from the former one by showing restricted 
reactivity essentially with neuroectodermal tumor cells as well as with embryonic and 
fetal brain cells of human origin. 
The results of investigations comparing immunostained tumor sections under 
varying conditions uggest hat the variability concerning the number of antibody 
binding cells in frozen sections and paraffin preparations is relative. The fact that each 
fixation and paraffin embedding led to remarkable r duction of positive cells indicate 
that many of tumor associated target determinants are destroyed by the used 
procedures. 
Based on the binding pattern of the antibodies MUC 7-22 to MUC 15-22 and 
MUC 2-63 to gliomas, the conclusion seems justified that these McAbs recognize 
different epitopes. This was confirmed by immunostaining of frozen and paraffin 
preparations ofthe same tumor, and cell cultures as well (Fig. 1, Table 3). Moreover, 
the binding behavior of preselected McAbs to human tumors of different origin (Tables 
1 and 2) indicated that neuroectodermal tumors hare similar antigens as described for 
spontaneous (Seeger et al. 1981; Carrel et al. 1982; de Muralt et al. 1985) and experi- 
mental neurogenic tumors (Stavrou et al. 1983). 
Particularly interesting is the observation that the McAbs obtained against 
astrocytomas (MUC 7-22 to MUC 15-22 and MUC 2-63) reacted not only with glioma 
cells but also with cells of the embryonic brain anlage, the fetal brain and other 
embryonic regions. Therefore, it is most likely that the antigens recognized by these 
antibodies represent oncoembryonal/oncofetal antigens expressed in cells during the 
prenatal period and also in brain tumor cells. These results correspond with observa- 
tions reported by Wikstrand et al. (1982) and de Muralt et al. (1985). 
The fact that McAbs directed against gliomas recognize molecules expressed in 
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glioma cells as well as in embryonic and fetal cells and even in reactive astrocytes (de 
Muralt et al. 1985) does not limit the application of such antibodies for immuno- 
diagnostic purposes. Regarding the histological and cytological examination of brain 
malignancies and the analysis of  tumor cells in the cerebrospinal fluid (Coakham et al. 
1985), well defined reagents, e.g. McAbs, provide valuable diagnostic tools. 
Although immunohistochemical studies are still in a preliminary stage, they are 
creating new perspectives for an objective intraoperative diagnostic ervice, especially 
in cases where only small fragments of  biopsy material are available. Moreover, McAbs 
directed against molecules restricted to embryonal/fetal tissue and re-expressed in 
malignant transformed brain ceils may serve as carders for radionuclides and cytostatic 
or cytotoxic agents in evaluation of in vivo diagnostic and therapeutic approaches as 
recently demonstrated for spontaneous and experimental neurogenic tumors (Bourdon 
et al. 1984; Epenetos et al. 1985; Stavrou et al. 1985, 1986a,b; Bullard et al. 1986). 
According to the different staining pattern of our McAbs recognizing up to 65 ~o of the 
cells within a glioma line one has to consider the possibility to increase the amount of 
positive cells by using a combination of  McAbs. 
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